SEP 4, 2026 · JOURNAL ARTICLE
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers
Cancer Research Communications
First-in-human Phase 1 dose escalation with primary focus on safety and tolerability; anti-tumor activity is secondary and minimal (2.5% ORR), consistent with early-phase exploratory work.
Reported
Sample size79
Maximum tolerated dose (without p…800 μg
Recommended expansion dose2100 μg